In practice, then, it really means we're talking about eight, nine or 10 meetings for that study, because after you hear the witnesses, there is usually a meeting to discuss instructions to the analysts for the report. Then there is usually at least one meeting—in my experience, it's usually two and sometimes three—to finalize the report.
Really, you're looking at somewhere between seven and 10 meetings for each of those studies. Add the fact that we already know a bill has been introduced in the House by the Minister of Health on the rapid tests. That's coming to this committee as well. We will not get to any other study besides the two we've talked about. In fact, we may not finish the children's health study by June, but hopefully we will.
The other thing is this. I don't know, but speaking for myself, the discussion we had, when we were blue-skying committee business, about having a series of short studies or longer ones.... That was never voted on or decided. It was a good idea, perhaps, but I don't think we ever came to a firm conclusion on that. That was an idea that was suggested by Mr. Berthold and then by Mr. Thériault.
In fairness, I don't think we came to a conclusion that this committee was going to have a series of short studies. The question really becomes, then, of all of the notices of motion, of all the potential studies that are on here, is this particular study of such pressing nature and of such widespread interest that it would warrant this committee's time?
I must say that I find it very granular. I've had the opportunity to have one discussion with Mr. Thériault about this, and similarly.... Our minds are in the generally same area, because I have a motion on breast health generally. That includes breast screening guidelines, wait times for diagnostic services, access to treatment, and options to improve health outcomes.
I think that could be broadened, like Mr. van Koeverden said, to include the very important issue of breast implant registry. However, with a breast implant registry itself, it would be very appropriate if we had decided to have targeted short studies. If we're not doing that, then it's very, very granular. In my opinion, it affects profoundly but a very small number of Canadians, whereas something like breast health generally affects, I'm going to say, 51% of the population. In fact, someone pointed out to me that breast health can affect men as well, but primarily it's women. We're talking about millions and millions of women who have an interest in access to timely breast screening and services and breast health.
Those are my general thoughts on this. We also have motions that have been moved on oral health, which I have moved, and substance use and addiction. In my respectful view, with great respect to the importance of this issue that Mr. Thériault was championing, I think they affect far more people and are of more urgency in terms of the impacts they have on a broad number of people. That's not to take away, of course, the significance of this issue to those who are interested in it.
I've been an MP for 14 years, and I don't think I've ever been contacted by anybody who has an issue over a registry of breast implants, but I have many, many people contacting me about a lack of access to dental care, or the opioid crisis, or breast health generally.
I'm happy to support this motion on the understanding that this vote not specify that we will be studying this issue as our third study. If that's okay with Mr. Thériault, then I'm happy to support it. I'd like him to clarify whether it's his intention, by passing this motion, for it to be the third study. If that were the case, I would move an amendment to broaden it to include breast health generally so that it includes not only the issues he wants to look at, which are important, but also the broader issues.